Conformational ensemble-based framework enables rapid development of Lassa virus vaccine candidates
Nitesh MishraiD, Gabriel AvillioniD, Sean CallaghaniD, Charlotte N. DiBiaseiD, Jonathan HurtadoiD, Nathaniel Steven LiendoiD, Sarah M. BurbachiD, Terrence Messmer, Bryan S. BrineyiD
Abstract
Lassa virus (LASV), an arenavirus endemic to West Africa, poses a significant public health threat due to its high pathogenicity and expanding geographic risk zone. LASV glycoprotein complex (GPC) is the only known target of neutralizing antibodies, but its inherent metastability and conformational flexibility have hindered the development of GPC-based vaccines. We employed a variant of AlphaFold2 (AF2), called subsampled AF2, to generate diverse structures of LASV GPC that capture an array of potential conformational states using MSA subsampling and dropout layers. Conformational ensembles identified several metamorphic domains--areas of significant conformational flexibility--that could be targeted to stabilize the GPC in its immunogenic prefusion state. ProteinMPNN was then used to redesign GPC sequences to minimize the mobility of metamorphic domains. These redesigned sequences were further filtered using subsampled AF2, leading to the identification of promising GPC variants for further testing. A small library of redesigned GPC sequences was experimentally validated and showed significantly increased protein yields compared to controls. Antigenic profiles indicated these variants preserved essential epitopes for effective immune response, suggesting their potential for broad protective efficacy. Our results demonstrate that AI-driven approaches can predict the conformational landscape of complex pathogens. This knowledge can be used to stabilize viral proteins, such as LASV GPC, in their prefusion conformation, optimizing them for stability and expression, and offering a streamlined framework for vaccine design. Our deep learning / machine learning enabled framework contributes to global efforts to combat LASV and has broader implications for vaccine design and pandemic preparedness.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies
H. R. Perrett, P. J. M. Brouwer, … A. B. Ward·bioRxiv·Sep 26, 2022
- Lassa virus glycoprotein nanoparticles elicit a neutralizing antibody that defines a new site of vulnerability
P. J. M. Brouwer, A. Antanasijevic, … R. W. Sanders·bioRxiv·Mar 28, 2022
- Prefusion-Stabilized Lassa Virus Trimer Identifies Neutralizing Nanobodies and Reveals an Apex-Situated Site of Vulnerability
J. Gorman, C. S.-F. Cheung, … P. D. Kwong·bioRxiv·Apr 21, 2022
- Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses
P. J. M. Brouwer, H. R. Perrett, … A. B. Ward·bioRxiv·Dec 21, 2023
- Deep mutational scanning reveals functional constraints and antigenic variability of Lassa virus glycoprotein complex
Caleb R. Carr, Katharine H. D. Crawford, … Jesse D. Bloom·ImmunityPeer-reviewed·Jul 15, 2024
- Machine Learning Reveals Key Glycoprotein Mutations and Rapidly Assigns Lassa Virus Lineages
Richard Olumide Daodu, Jens-Uwe Ulrich, Denise Kühnert·bioRxiv·Jul 31, 2024